Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alpha 1 antitrypsin - CSL Behring

Drug Profile

Alpha 1 antitrypsin - CSL Behring

Alternative Names: AAT - CSL Behring; Alpha-1 proteinase inhibitor - CSL Behring; Alpha-antitrypsin - CSL Behring; API; API Inhale; CSL 964; Respreeza; Zemaira

Latest Information Update: 04 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSL Behring
  • Developer Blood and Marrow Transplant Clinical Trials Network; CSL Behring; Nektar Therapeutics
  • Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Antiallergics; Antihyperglycaemics; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
  • Mechanism of Action Alpha 1-antitrypsin replacements; Immunomodulators; Serine endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Alpha 1-antitrypsin deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alpha 1-antitrypsin deficiency
  • Phase III Graft-versus-host disease

Most Recent Events

  • 02 Jan 2024 Preregistration for Alpha 1-antitrypsin deficiency in Puerto Rico, Mexico (IV), prior to January 2024
  • 02 Jan 2024 Registered for Alpha 1-antitrypsin deficiency in Puerto Rico, Mexico (IV), prior to January 2024
  • 17 Nov 2021 Phase-III clinical trials in Graft-versus-host disease (In adolescents, Prevention, In adults) in Spain, USA, Australia, United Kingdom, Italy, Germany (IV) before November 2021 (CSL Behring pipeline, November 2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top